These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29328503)

  • 1. Challenges and Opportunities With Oncology Drug Development in China.
    Bajaj G; Gupta M; Wang HH; Barrett JS; Tan M; Rupalla K; Bertz R; Sheng J
    Clin Pharmacol Ther; 2019 Feb; 105(2):363-375. PubMed ID: 29328503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
    Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
    Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
    Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug approvals in oncology.
    Kurzrock R; Kantarjian HM; Kesselheim AS; Sigal EV
    Nat Rev Clin Oncol; 2020 Mar; 17(3):140-146. PubMed ID: 32020042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer drug development in China: recent advances and future challenges.
    Wu YL; Zhang H; Yang Y
    Drug Discov Today; 2015 Jun; 20(6):766-71. PubMed ID: 25463037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities in oncology drug development and clinical research in China.
    Wang F; Ruan DY; Xu RH
    Cell; 2024 Mar; 187(7):1578-1583. PubMed ID: 38552607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RACE to accelerate drug development for children with cancer.
    Pearson ADJ; Karres D; Reaman G; DuBois SG; Knox L; Scobie N; Vassal G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):714-716. PubMed ID: 32822672
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
    Amiri-Kordestani L; Pazdur R
    Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid advances in research on and development of anticancer drugs in China.
    Yao X; Du N; Hu S; Wang L; Gao J
    Biosci Trends; 2019 Nov; 13(5):461-463. PubMed ID: 31511442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps.
    Printz C
    Cancer; 2020 Jan; 126(2):239-240. PubMed ID: 31917472
    [No Abstract]   [Full Text] [Related]  

  • 11. [Future cancer care challenges the health care].
    Olofsson S
    Lakartidningen; 2010 Apr 21-27; 107(16):1065. PubMed ID: 20476702
    [No Abstract]   [Full Text] [Related]  

  • 12. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
    Ji Y; Jin JY; Hyman DM; Kim G; Suri A
    Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
    Lyman GH
    J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
    [No Abstract]   [Full Text] [Related]  

  • 15. ASCO 2011: broadening the horizons of cancer research.
    Crane K
    J Natl Cancer Inst; 2011 Jul; 103(13):999-1001. PubMed ID: 21693729
    [No Abstract]   [Full Text] [Related]  

  • 16. [Introduction].
    Koch M; Monneret C
    Ann Pharm Fr; 2005 Jan; 63(1):4-6. PubMed ID: 15803093
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in drug development: off-label drug utilization in oncology.
    de Souza JA
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):473-5. PubMed ID: 21841748
    [No Abstract]   [Full Text] [Related]  

  • 18. Repurposing Drugs in Oncology: Next Steps.
    Verbaanderd C; Meheus L; Huys I; Pantziarka P
    Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From biology to innovating treatments for tumors: a long struggle].
    Thiery JP
    Ann Pharm Fr; 2005 Jan; 63(1):7-9. PubMed ID: 15803094
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalised medicine in paediatric oncology: Ethical practice outside the clinical trial framework?
    Hansford JR
    J Paediatr Child Health; 2019 Jan; 55(1):10-12. PubMed ID: 30499210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.